Skip to main content
Clinical Trials/NCT01433094
NCT01433094
Completed
N/A

Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia

University of Cagliari8 sites in 1 country112 target enrollmentSeptember 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Patient Non-Compliance
Sponsor
University of Cagliari
Enrollment
112
Locations
8
Primary Endpoint
Adherence
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Background: Psychosis in the spectrum of schizophrenia (PSS) are severe mental disorders, with a high impact on disability and participation. Poor adherence to pharmacotherapy negatively impacts on the course and outcome of PSS.

Non-adherence in these patients is 41 to 50%, and it is predictive of a higher risk of relapse and readmission up to 5-time higher than in adherent patients. Falloon et al. developed a Psychoeducation Program (FPP) aimed at improving communication and problem-solving abilities in patients and their families. Past studies reported a statistically significant reduction of the risk of relapse in patients receiving the FPP, but did not take into account effects on adherence.

Objectives: To evaluate changes in adherence to pharmacotherapy in a sample of patients diagnosed with PSS (ICD-10: F20 to F29), by comparing a group exposed to the FPP with another group exposed to a treatment with generic informative prospects on the disorders provided with same attendance frequency as the FPP (Generic Treatment - GT).

Methods: 340 patients with PSS, from 10 participating units distributed in the territory of the Italian National Health System, will be enrolled, with allocation 1:1. The sample will be randomized into an exposed group (to FPP) and an unexposed group. Adherence will be assessed on a three-monthly basis with blood levels of the primary prescribed drug by High Pressure Liquid Chromatography, with a self-report, the Medication Adherence Questionnaire, and concurrently with the administration of a 4-item interview, based on a modified version of the Adherence Interview. Survival analyses will be performed using Kaplan-Meier method, followed by Log-rank test, defining as terminal events both the start of non-adherence and/or the first relapse or readmission episode. Intention-to-treat will be applied in considering the primary and secondary outcomes. Multiple imputations will be applied to integrate missing data.

Expected results: Median prevalence of non-adherence to pharmacotherapy in patients already in contact with a psychiatric service is 47%; effect size of psychosocial treatment on various outcomes, including relapse, readmission and adherence to drug is 0.48 of the standard deviation (SD), with 95% C.I.=0.10 to 0.85. The intervention is expected to produce a change in the prevalence of non-adherence to drug in the exposed group with an effect size of 0.45 SD.

Registry
clinicaltrials.gov
Start Date
September 2012
End Date
December 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

donatella rita petretto

Assistant Professor

University of Cagliari

Eligibility Criteria

Inclusion Criteria

  • diagnosis of psychosis in the spectrum of schizophrenia (ICD-10: F20 to F29); -age from 18 to 55;
  • being in care for 2 years or more.

Exclusion Criteria

  • mental retardation, or any severe cognitive impairment;
  • psychosis due to substance abuse or to a medical condition;
  • affective psychosis;
  • comorbid substance dependence;
  • patient does not understand Italian language;
  • pharmacotherapy with depot.

Outcomes

Primary Outcomes

Adherence

Time Frame: Change from baseline in adherence to treatment at 6 months

Adherence will be checked with a triple method of assessment: patient's self-report, patient's replies to a four-query interview, and assessment of blood levels of the prescribed drug.

Secondary Outcomes

  • Readmission(Occurrence of episodes of readmission over 27 months)
  • Changes in the social functioning(Changes from baseline in social functioning at 6 months, maintained at 12 and 18 months)
  • Psychotic symptoms(Changes from baseline in levels of psychotic symptoms at 6 months, with effects maintained at12 months and 18 months)
  • General level of psychopathology(Changes from baseline in levels of general psychopathology at 6 months, with effects maintained at 12 and 18 months)

Study Sites (8)

Loading locations...

Similar Trials